Skip to content

Booksellers & Trade Customers: Sign up for online bulk buying at trade.atlanticbooks.com for wholesale discounts

Booksellers: Create Account on our B2B Portal for wholesale discounts

Clinical Trial Modernization: Technological, Operational, and Regulatory Advances

by Harry Yang , Liang Zhao
Save 35% Save 35%
Current price ₹11,876.00
Original price ₹18,270.00
Original price ₹18,270.00
Original price ₹18,270.00
(-35%)
₹11,876.00
Current price ₹11,876.00

Imported Edition - Ships in 12-14 Days

Free Shipping in India on orders above Rs. 500

Request Bulk Quantity Quote
+91
Book cover type: Hardcover
  • ISBN13: 9781032123608
  • Binding: Hardcover
  • Subject: N/A
  • Publisher: CRC Press
  • Publisher Imprint: CRC Press
  • Publication Date:
  • Pages: 412
  • Original Price: GBP 140.0
  • Language: English
  • Edition: 1
  • Item Weight: 781 grams
  • BISAC Subject(s): Probability & Statistics / General

As the pharmaceutical industry navigates this new era of technological innovation, the integration of AI, big data, and advanced analytics into clinical trials holds immense potential to transform drug development. Clinical Trial Modernization: Technological, Operational, and Regulatory Advances provides a comprehensive overview of the current trends, challenges, and opportunities in modernizing clinical trials, offering a roadmap for stakeholders in this evolving field.

This book serves as a valuable resource for professionals, researchers, and regulators, providing actionable insights into the future of clinical trials and their critical role in bringing new therapies to market faster and more effectively.

Harry Yang, Ph.D., is Vice President of Biometrics at Recursion Pharmaceuticals. With over 25 years of experience in small molecule, biologics, and cellular immunotherapy development, his expertise spans the therapeutics areas of transplantation, vaccines, autoimmune and inflammatory disease, rare disease, and oncology. Dr. Yang is well-versed in innovative clinical trial design, regulatory submissions, and integration of real-world data, AI, and machine learning in drug R&D. He is a prolific author, having published 9 books and over 130 articles and book chapters covering critical statistical, scientific, and regulatory topics in drug R&D.

Liang Zhao, Ph.D., is Professor of Bioengineering and Therapeutic Sciences at University of California, San Francisco, following his role as the Director of Division of Quantitative Methods and Modeling (DQMM), Office of Research and Standards, Office of Generic Drugs, CDER/FDA. Dr. Zhao has introduced a broad array of innovative tools in drug deliveries, bioequivalence assessment, and pharmacometrics. He has published 100+ articles and book chapters and is the recipient of the 2023 Gary Neil Prive for Innovation in Drug Development from ASCPT.

Trusted for over 49 years

Family Owned Company

Secure Payment

All Major Credit Cards/Debit Cards/UPI & More Accepted

New & Authentic Products

India's Largest Distributor

Need Support?

Whatsapp Us